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An approach to revolutionize cataract treatment by enhancing drug probing
through intraocular cell line
Ling Wang, Weixian Liu and Xionggao Huang
Department of Ophthalmology, The First Affiliated Hospital of Hainan Medical College, Haikou, Hainan, China
ABSTRACT
The purpose of this study is to prepare and characterize solid lipid nanoparticles (SLN) of N-Acetyl
Carnosine (NAC) to treat cataract since surgery necessitates equipments and professional help.
Cataract is believed to be formed by the biochemical approach where the crystalline eye proteins
lose solubility and forms high molecular weight masses. Added advantages of SLN of NAC
(henceforth referred as SLN-NAC) in the study are reduced size, sustained release and better corneal
penetration of drug. The method of preparation of SLN-NAC by Mill’s method is unique in itself.
The size of the SLN-NAC was 75 ± 10 nm in the range of ideal for penetration. The in-vitro
release study and the SLN-NAC formulations prepared with Mill’s method demonstrated
sustained release up to 24 h following an initial burst after 1 h. The zeta potential of the
prepared formulation was −22.1 ± 1 mV. Corneal permeation studies using goat corneas
indicate that SLN-NAC penetration rate was higher than those from NAC eye drops. Corneal
hydration studies indicated that the formulation caused no harm to the corneal cells.
Therefore it may be concluded that SLN-NAC may revolutionize cataract treatment and
reversal by improving drug permeation, reducing toxicity and no damage to corneal tissue.
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Eye is an intricate organ isolated by blood–ocular bar-
riers which includes retinal, aqueous and vitreous humor
making it a primary and accessible site for drug delivery
investigations [1]. The main way of administering a drug
for any eye disorder is ophthalmic application but the
conventional formulations ensure only a limited amount
of drug penetrating these barriers. Although eye is gen-
erally protected, but still problems relating to age like
cataract frequently surface and treatment of cataract
generally leads to a single outcome – surgery [2] and
intravitreal procedures associated with numerous side
effects like detachment of retina [3]. Cataract may be the
chief cause of blindness in 50% of cases worldwide. The
principal cause of cataract is ageing and frequently
other associated factors may be exogenous like UV
radiation and trauma causing accidents or endogenous
like diabetes and genetics [2]. Surgery has been the
most established and effective treatment for reversing
cataract except for the fact that this requires medical
expertise and instrumentation. These two factors are
limiting since they are not available everywhere. Hence
there is an immediate need for non-invasive techniques
for treatment and reversal of cataract.
Cataract is believed to be formed by the biochemical
approach where the crystalline proteins lose solubility
and forms high molecular weight masses [4,5].
Moreover aggregation of these despite the durable
crystalline and chaperone concentration may lead to
insoluble proteins. It is also known to have formed
from oxidative stress. N-Acetyl Carnosine (NAC) is an
ophthalmic drug which shows potential for treatment
or even reversal of cataract [6–8]. A known antioxidant
effect of the protein, L-carnosine, on cataractuous lens
may allow us biochemically for exploring L-carnosine as
a cause to converse or even avert development of cat-
aract [9,10]. L-carnosine cannot penetrate the eye as an
eye-drop. However, when smeared on the surface of the
eye, NAC penetrates the cornea into the front chamber
of the eye close to the place where the cataractuous lens
is and there is metabolised into L-carnosine [7].
Deterrence and reversal of cataract by carnosine are
mediated by various mechanisms like inactivation of
lens proprietary antioxidant enzymes induced by free-
radical (superoxide dismutase); inhibition of cross-link-
ing glycation reactions to the lens proteins induced by
auto-oxidation of ascorbic acid which is in turn cata-
lyzed by carbohydrate and metal; carnosine having
transglycation properties which permits it to contend
for the glycating agent, shielding proteins (lens crystal-
lins) alongside alteration; common antioxidant and
scavenging properties towards lipid hydroperoxides,
aldehydes and oxygen radicals; L-carnosine ingredient
of proteasome activity within the lens; NAC and its
bioactivated primary component carnosine also causes
disintegration of lens crystalline activity.
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It has been observed in numerous studies that
nanoparticulate systems are capable of penetrating
the cornea of the eye more efficiently as when
compared with the free drug [11–17]. Nano-bio-
technology in clinical research has led to abundant
pathbreaking therapeutics. The unique possibilities
of nanoparticles like reducing toxicity of a drug and
biocompatibility make them excellent nanocarriers
for therapeutic purposes [18]. Nanoparticulates also
help in achieving the most important feature of
ocular drug delivery that is equal bioavailability
due to their reduced size [19]. Moreover, nanopar-
ticulates are not easily removed from the ocular
area because of blinking or tear mechanism as
compared to free drug [16,20].
Therefore in our study, we prepared the solid
lipid nanoparticles (SLN) of NAC for prevention of
cataract. Henceforth we will be referring to them
as SLN-NAC. SLNs are microscopic colloidal expor-
ters alternating between 50 and 1000 nm, made of
biological lipid, distributed in water or in aqueous
surfactant solution [21]. These are appropriate for
the assimilation of lipophobic, hydrophobic, and
low water solvable drugs [22]. It has been con-
cluded that for ocular drug delivery SLNs are
extreme stable, maximum efficiency of entrapment
and are promising carriers of ocular drugs like
meloxicam [23]. The purpose of the study was to
formulate NAC loaded-SLN preparations as con-
stant eye drug delivery systems with the aim of
improving obtainability and sustainability of NAC
at the corneal level. The current study was based
on the lines of a similar study of encapsulating
NAC in PLGA polymer for increased drug availabil-
ity for cataract treatment [24]. However, in our
study, preparation of SLN of NAC was carried out
to ensure decreased toxicity and relatively more
stability. Another novel achievement was the
development of human corneal cell construct
from human endothelial cell line for the drug per-
meation studies.
1.1. Design considerations for SLN-NAC
The size of the SLN-NAC will determine its function-
ality like uptake of the nanoparticles by ocular tissues,
adherence to cell layer, sustainability and clearance
from the ocular region. It was approximated from
various studies that size of 10–400 nm will allow
better passage of nanoparticulates into the deeper
layers of ocular structure for prevention of cataract
[17,18]. The preparation technique of the SLN-NAC
will ensure that the nanoparticles will be transformed
from lipophilic to hydrophilic and also may reduce the
irritation of the eye. This was designed to be an ideal
ocular drug delivery system which may possess the
essential features mentioned above.
2. Methodology
2.1. Material
Raw material of NAC, precisely the L-isomeric form of
was produced at the cGMP facility. Zirconia beads and
Bead Smash 12 (a bead mill) was acquired from
Wakenyaku Co. Ltd, Kyoto, Japan.
HENC, elaborated as Human corneal endothelial
cells, Endothelium stroma equivalent and Epithelial
cells (CEPI 17 CL4) were procured from Thermo
Fisher Scientific, Beijing, China. Ham’s F12 and
Medium F99, FCS an antibiotic and antimycotic were
procured from Sigma, China. All other chemicals were
procured from Sigma Beijing, China.
Sosium Selenite for inducing cataract in HENC for
impedance studies was also procured from Sigma, China.
2.2. Cell culture
HENC are normal human corneal endothelial cells
isolated elsewhere and more than 5 × 105 viable
cells are contained in each vial of this product which
was cryopreserved at the culmination of the second-
ary culture level. The cells were thawed and seeded
and cultured in Medium F99, which is the amalgama-
tion of Ham’s F12 and Medium F99 in the ratio of 1:1
and 5% FCS and 1% antibiotic/antimycotic solution
was added to above media according to the instruc-
tions provided [25–28].
25 cm2 tissue culture flasks (Costar) were utilized
for conservation of the cultures in regular conditions
at 37 °C in a moistened atmosphere having 5% CO2.
Replacements of growth medium were carried out
thrice every week.
2.2.1. Human corneal construct
A step by step in-vitro corneal cell construct was
prepared from the HENC as described by Reichl et al
and Kawazu et al [25,29]. 2 × 106 cells were seeded
onto a 4.7 cm2 surface area containing polycarbonate
filter with pore size of 3.0 mm. These were concealed
with a layer of type I collagen and matured to con-
fluence in a time span of 7 days in medium F99. A
type I collagen gel matrix comprising of stromal fibro-
blasts was layered over the endothelial cell layer
which was already confluent. Equivalent of endothe-
lium stroma was cultured after 4 days of submergence
in DMEM media. Epithelial cells (CEPI 17 CL4) at a
concentration of 1.5 × 105 were cultured onto the
contracted lattice of collagen and developed in cul-
ture medium DMEM/F12 for further 7 days until con-
fluence was achieved. Following the confluence of the
epithelium, tissue construct was elevated to the air–
liquid interface was carried out for further 12 days and
cultured in DMEM/F12 media with the serum content
lessened to 2%. In a span of 12 days, a multilayered
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epithelium was designed. An incubator which was
humidified at 37 °C containing 5% CO2 was used to
sustain the cultures with replacement of medium
three times per week.
2.3. Preparation of SLN-NAC
The conventional preparation of SLN-NAC was done
following the Mill method described by Nagai and Ito
[17] with suitable modifications. The zirconia beads
(diameter: 2 mm) were supplemented with NAC
microparticles (solid) containing methylcellulose (MC)
and with the bead mill for 30 s @ 3,000 rpm, the
mixtures were smashed at 4°C. The mixes were dis-
seminated in saline with 5% 2-Hydroxypropyl-β-cyclo-
dextrin (HPβCD), and smashed over again with the
bead mill @ 5,500 rpm, 30 s ×15 times at 4 °C utilizing
lesser sized zirconia beads which were of diameter of
0.1 mm. SLN-NAC were obtained by the bead mill
method and alongside there was no precipitation of
nanoparticles in the dispersion mixes after 7 days of
preparation.
2.3.1. Lyophilization of the nanoparticles
Khare et al [18] and Huang et al [30] described a
simple protocol of lyophilization of nanoparticles
which was followed with suitable modifications.
2.5% w/v mannitol was mixed as a cryoprotectant to
the above prepared dispersion followed by lyophiliza-
tion executed for 24 h to check physical stability and
redispersibility of the mix. To begin with, pre-freezing
was completed by freezing the mixture at −74 °C, at
0.02 mmHg pressure, in vials which were then trans-
ferred into the adapter. The adapter was then fit into
freeze-dryer Lyophilizer FD-5–3, and lyophilized pow-
der of SLN-NAC was obtained
2.4. SLN-NAC characterization
The morphological investigation of the SLN-NAC was
done with the help of a high-resolution transmission
electron microscopy (TEM, JEM-2010HR). Briefly, the
liquid solution was positioned on the copper grid and
then staining was carried out with Phosphotungstic acid.
Further sample were air dried and incubated for 3 h.
2.5. Size distribution and stability of formulation
The average size distribution of SLN-NAC was deter-
mined using Malvern zeta sizer (Malvern Instrument
Inc,). The samples were diluted with PBS and uniformly
dispersed with ultra-purified water and the analysis was
performed. The SLN-NAC was characterized with Zeta
potential. The measurements were executed using an
aqueous dip cell in an automatic manner by insertion of
diluted samples in the capillary measurement cell and
position of cell was attuned.
The prepared formulation was studied for particle
size distribution and electrical properties by zeta
potential measurement. Zeta potential is a significant
procedure for characterization of surface morphology
that supports defining the probable stability and
charge on the surface of the nanoparticulate struc-
ture. Usually for colloidal dispersion stability, com-
plete large negative or positive zeta potential values
are necessary as aggregation of nanoparticles may be
avoided by electrostatic repulsion amongst particles
with identical charges.
The experiments were performed thrice and the
results were discussed as mean ± SD.
2.6. Determination of % of drug trapped in
SLN-NAC
This was carried out by a protocol described by Khare
et al [18]. Entrapment efficiency is described as the
percentage of the actual drug mass captured in the
polymeric carrier, comparative to the original amount
of drug loaded, and was calculated using the follow-
ing equation:
Entrapment efficiency% ¼ ActualDrugLoading
Theoreticaldrugloading
 100 (1)
Calculation of theoretical drug loading was performed
with the following equation from the quantity of drug
taken comparative to the quantity of total drug and
excipients utilized for preparation of SLN-NAC:
Theoreticaldrugloading% ¼ Totaldrug
TotalDrug þ TotalExcipients (2)
Actual drug loading was done utilizing the following
procedure: a SLN-NAC dispersion was set by dissolving
25 mg of the lyophilized powder of SLN in 5mLmixture
of methanol: distilled water (1:4) and was centrifuged
for 20 min @ 13,000 rpm. The clear supernatant was
noted for free NAC residue by assessing absorbance at
255 nm in an UV-visible spectrophotometer. The entire
quantity of drug existing in the SLN-NAC was calcu-
lated by dissolving the lyophilized 25 mg of SLN-NAC
powder in 10 mL dichloromethane by sonication and
thereafter straining it through a microsyringe filter
(0.2 µm) and evaluating the remains for NAC by calcu-
lating absorbance at 255 nm using UV visible spectro-
photometer [31]. The succeeding formula calculated
the actual drug loading percentage:
ActualDrugLoading% ¼ TotalDrug  Freedrug
MgofLyophilizedpowder
 100 (3)
2.7. In-vitro drug release from the SLN-NAC
This is an extremely important experiment since the
release of the NAC from the nanoparticles will deter-
mine whether this technique can be effectively
implied in ocular drug delivery. 1 mL of phosphate
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buffered saline (PBS; pH 6.8) was utilized to dissolve
5 mg of incubating SLN-NAC lyophilized powder with
horizontal shaking at 37 °C. The release investigation
began by insertion of the end-sealed dialysis bag into
50.0 mL of simulated tear fluid (pH – 7.4) at 37 °C with
persistent pulsating. At particular time interims,
3.0 mL of simulated tear fluid was drawn and
reloaded with an identical quantity of freshly pre-
pared tear fluid. Data were obtained in triplicate and
analyzed through graph; that is, % drug release versus
time graph was plotted.
2.8. FTIR studies
The infra-red (IR) spectra provides description regard-
ing the functional groups and their location in a novel
drug formulation. Henceforth, IR spectra of NAC and
SLN-NAC were analyzed utilizing Fourier transform
infrared (FT-IR) spectrophotometer with total reflec-
tance (ATR) mode (Shimadzu, Kyoto, Japan) for
detailed analyses of the functional groups. The peaks
noted in the ATR spectrum were interpreted and
equated with known values.
2.9. Impedance measurement
The impedance sensing devices were purchased from
Applied Biophysics and used to measure impedance
of cultured adherent HENC on its electrode surfaces.
The HENC cells were treated with 100 µm sodium
selenite, an oxidative stress inducing agent for start-
ing a cataract infection [32]. The cataract induced cells
were treated with 10 µl vol/wt NAC, PBS (control) and
SLN-NAC. Impedances of treated and control samples
were measured after 48 h of inoculation within a
frequency limit from 100 Hz to 1 MHz in a logarithmic
scale. The ECIS device consisted of eight wells and
each well possessed 10 gold microelectrodes (250 μm
diameter) which sense flow of current within the
solution as described by Benson et al [33]. The sub-
strate area was 0.8 cm2 and the volume of each well
was 600 μl. The ECIS devices were equilibrated over-
night with cataract induced HENC in a tissue culture
incubator. Then more cataract induced cells were
added to the well in 300 μl media for impedance
measurement.
Subsequently the impedance data was incorpo-
rated into ZsimpWin (Ver. 3.10) for fitting it. The com-
parable circuit was attained from investigations by
Dou et al [34] and Gong et al [35].
2.9.1. Statistical data analysis
All the experiments including impedimetric analysis
and cell assay were carried in triplicate and the data
were represented with their corresponding relative
standard deviations (RSD).
2.10. Drug permeation studies
Three aqueous solutions containing NAC and SLN-NAC
were utilized for studies for diffusion for the assessment
of cell permeability at 37 °C using revised Franz diffusion
cells. The drug permeation studies were done over the
human corneal construct. The protocol was adapted from
Reichl et al [25] with some necessary modifications. The
donor drug formulation had NAC 2% and SLN NAC 2%.
The receiver solution comprised of isotonic PBS with pH
7.4 and was agitated with utilizing a magnetic stirrer at
400 rpm throughout the study. At a regular gap of
60 min, from the receiver chamber the samples were
collected and quantitatively investigated by high-perfor-
mance liquid chromatography (HPLC). Calculation of the
amounts (mg/cm2) of drug infused through the corneal
construct versus the time (minutes) revealed the permea-
tion parameters of SLN-NAC and NAC. Calculation of
permeation coefficient KP was conceded as drug concen-
tration from the rectilinear gradient of a permeation
curve. Apart from this, drug permeation was also seen
by staining the corneal constructs with H&E as per the
protocol described by Reichl et al [25].
2.10.1. Statistical analysis
Data investigation and quantification were achieved by
Waters Millenium 32 Chromatography Manager software
(Waters) and also by Origin 8. The data was represented
asmean ± SD (standard deviation) of five determinations.
2.11. Corneal hydration studies
The whole corneal planning technique was adopted
from Khare et al [18] with suitable modifications and
had to be completed within 1 h of the goat sacrifice.
Proper institute ethical clearance for large animals
was obtained for the studies. Entire eyeballs of freshly
sacrificed goats were acquired from a local dealer and
sent to the research laboratory ice-cold in normal
saline (4 °C). Cautious excision of the cornea was
then performed together with 2–4 mm of adjacent
scleral tissue and was readied using normal saline
until the sample was protein free. Subsequently,
each cornea was unencumbered from adhered sclera
and treated with SLN-NAC and NAC. After the respec-
tive treatments, 1 ml methanol was used to soak the
cornea which was then dried overnight at 80 °C, and
weighed again. Calculation of corneal hydration was
done after noting the differences in the weights.
2.12. Cytotoxicity test
Cytotoxicity of NAC and SLN-NAC evaluated according
to Banerjee et al [36] and Dou et al [34] with appropriate
modifications. Confluent HENC cultures were obtained
as mentioned in procedure above. For the estimation of
in-vitro cytotoxicity, MTT assay was being done. Cells
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were harvested at 5 × 103 cells/well in 96-well plates and
incubated for 72 h ensuring that cells are viable on
addition of the following; 0.1 mL of PBS (control), NAC
nanoparticles (0.1 mg/ml) and SLN-NAC (0.1 mg/ml).
These were incubated for 24 h. 0.1 mg/ml was selected
as the dose since it is regularly used for ophthalmic
formulations. Then, 20 μL of MTT solution (5 mg/mL)
was added in eachwell and the plates were incubated at
37°C for 4 h. The absorbance was measured at 492 nm
after the incubation using a microplate reader.
3. Results
3.1. Human corneal cell constructs
The novel bioengineered corneal construct consists
of a cell layer comparable to stroma encompassing
inherent fibroblasts, endothelium lying under-
neath, topped with stratified epithelium which
was derived from HENC and CEPI 17 CL4 respec-
tively. A mosaic like pattern was observed when
stained with haematoxylin and eosin (H&E) and
viewed in phase contrast micrography as depicted
in Figure 1. In order to express the multilayer
epithlium, the construct was lifted to air–liquid
interface and from the Figure 1, it can be clearly
seen. The basal cell layers appear flattened. This
agrees with other corneal construct studies done
before [25–28] and also in corneal in-vivo.
3.2. Size distribution and stability of formulation
Particle size distribution is a significant parameter
towards progress of suitable nanoparticulates for
therapeutic resolutions. It determines in-vivo drug
release behaviour, biological fate, toxicity and the
specific targeting of SLN-NAC after administration.
Also it can also affect the loading, release and
stability of drug (NAC) inside SLN. The diameter
distribution of the SLN-NAC varied from 65 to
85 nm. The particle size distribution is shown in
Table 1. The measurements were done thrice and
results given as mean ± SD. The zeta potential
ranges from −22.1 to ± 1 is also shown in Table 1.
The zeta potential can greatly influence the stability
of the nanoparticles.
3.3. Transmission electron microscopy of SLN
NAC
Morphological examinations of the SLN-NAC were done
utilizing TEM. This study depicted that all the SLN-NAC
prepared were spherical in shape albeit a little obtuse
towards the circumference without any rough or sharp
edges as seen in Figure 2(a,b). The particles were suffi-
ciently small enough to avoid sedimentation.
3.3.1. Determination of % of drug trapped in
SLN-NAC
Table 2 summarizes the entrapment efficiency of the
SLN-NAC. It is clearly calculated that the entrapment
efficiency is 86% i.e. entrapment efficiency is deter-
mined that if the % occurs to be 86, then it is assumed
that in 1 mg of nanoparticles there is 0.86 ml of drug.
Actual drug loading was calculated to be 8% which is
a comparatively high drug loading.
Figure 1. Human Corneal cell construct.
Table 1. Size distribution and Zeta Potential measurement of
SLN-NAC.
Formulation
Average particle Size (nm) ± SD
(n = 3)
Zeta Potential ± SD
(n = 3)
SLN-NAC 75 ± 10 −22.1 ± 1
Figure 2. TEM micrographs of SLN-NAC.
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3.4. In-vitro release of SLN-NAC
In-vitro release of the drug from SLN-NAC is depicted in
Figure 3. The graph shows a steady release of drug from
the solid lipid nanoparticles. The release of NAC at the
end of 1 h was 17.89 ± 0.23% and after 24 h it was
88 ± 0.23%. Therefore, after an initial burst of drug,
there was a steady release of NAC which is important
for treatment of cataract since NAC eye drops will tend to
wash away immediately after application. With SLN-NAC
aside from an initial burst, there is a steady sustained
release of the drug for quite a long time before drug
renewal. The corneal residence time for SLN-NAC is much
longer than free NAC.
3.5. FTIR studies
The ATR spectra were recorded from 4000 to 650 cm−1
as depicted in Figure 4. The NAC molecule exhibited
the chief peaks contributed by the functional groups of
molecules, such as carbonyl – C = O stretching
(1649 cm−1), – CH, – CH2, and – CH3 stretching
(2920–3850 cm−1), – O–H and – N–H stretching
(3564–3343 cm−1), and – C–N stretching (1000–
1339 cm−1). The SLN-NAC also exhibited similar types
of functional groups only the difference lies in the
absence of some peaks in the region especially in
1000–1339 cm−1. This may be due to the fact that
concentration of NAC found in pure drug may not be
present in the SLN-NAC.
3.6. Impedance measurement
Bode plot for the effect of NAC and SLN-NAC on cataract
induced HENC line is presented in Figure 5. A normal
HENC line is also plotted as control. The investigational
data are fitted quite well with the used equivalent circuit
as represented in Figure 5. It is evident from the Figure 5
that the impedance increases for SLN-NAC treated sam-
ple as compared to free NAC treated and control sam-
ples. The impedance curve for SLN-NAC treated cataract
induced sample moves towards the curve for normal
HENC sample. Thus it can be interpreted that SLN-NAC
may treat the cataract infection and cause its reversal. It
is also verified from the results that the SLN-NAC are
adept at initial burst release and subsequent sustained
release of the incorporated drug in order to achieve the
desired results. The relative standard deviations (RSD)
for SLN-NAC, NAC treated and control are found to be
below 10% that proves the data of the experiments is
reproducible.
3.7. Drug permeation studies
The permeation profiles of SLN-NAC and NAC are
represented in Figures 6 and 7. Graphically presented
Figure 6 depicts the drug permeation in corneal con-
struct for a period of 24 h considering the release of
drug from SLN-NAC over the same period. It is seen
that about 64 ± 3% of SLN-NAC permeates through
the corneal membrane as against 38 ± 1% of free
Table 2. Percentage of drug loading SLN and the percentage
of entrapment of drug in the SLN-NAC.
Formulation Drug Loading % Entrapment efficiency %
SLN-NAC 8 ± 0.65 86.16 ± 2.4
Figure 3. in-vitro release profile of SLN-NAC.
Figure 4. FTIR spectra of NAC and SLN-NAC.
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NAC. Therefore a higher permeability of SLN-NAC as
compared to free NAC is demonstrated which is cor-
roborated by the microscopic images in Figure 7. The
human corneal construct shows good permeability in
both SLN-NAC and a little less permeability with free
NAC although it is to be noted that corneal construct
acts as a lipophilic-hydrophilic barrier to both SLN-
NAC and free NAC. The SLN-NAC crosses the cell
membrane to embed deep in the cell construct
whereas free NAC is more concentrated on the mem-
brane with less amount being able to permeate in.
3.8. Corneal hydration studies
Corneal hydration was calculated and depicted in
Figure 8. The corneal hydration for SLN-NAC treated
cornea was 79% whereas it is 72% in case of free NAC
treated one. Normal corneal hydration is between
75% and 80% [37]. Hence the corneal hydrations stu-
dies depict that was no corneal damage on treatment
with SLN-NAC.
3.9. Cytotoxicity studies
Cytotoxicity of the NAC and SLN-NAC is clearly
demonstrated in Figure 9. We know from the control
study the cells were completely viable at the begin-
ning of the experiment. But it is interesting to know
that the cell toxicity of the NAC and SLN-NAC is not
significantly different from the control.
4. Discussion
We know from the previous investigations that con-
current culturing of each corneal cell type with extra-
cellular matrix, collagen type I, within which epithelial,
stromal, and endothelial cells may intermingle in-vitro
and in-vivo identically. Additionally, culturing at air–
liquid interface has a profound effect on the growth
of a resilient, beehive styled epithelium that is multi-
layered [25]. Keeping these points in mind, we had
designed our study process so that the corneal con-
structs may prove a great equivalent replica of human
cornea. This may help a long way in studying the SLN-
NAC in comparison with only NAC for effective catar-
act reversal and treatment. Only factors which marks
the difference is the absence of lachrymal fluid and
eye blinking, apart from which the layers of cell are
very similar. Along with corneal constructs, HENC line
was cultured along to investigate the drug
Figure 5. Impedance profiles of Normal HENC cells, SLN-NAC
treated HENC cells, Free NAC treated HENC cells and cataract
induced HENC cells.
Figure 6. Percentage of SLN-NAC and NAC permeation in
human corneal construct.
Figure 7. (A) Drug permeation of SLN-NAC; (B) Drug permeation of NAC in human corneal construct.
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permeation and impedance studies. Although the
drug permeation studies could have been done in
freshly excised cornea as in corneal hydration studies,
intraocular immortalised HENC line was preferred
since cornea may be a bit less permeable to the
drugs because of its state [16]. Moreover for impe-
dance studies we needed a cell line where cataract
could be induced to compare the effectiveness of
SLN-NAC and free NAC for treatment and reversal of
the condition.
The novel bead mill method of preparation of SLN-
NAC was preferred over the standard microemulsion
and ultrasonication methods. The reason here lies was
to elucidate any corneal toxicity of the SLN-NAC and
allow better penetration of nanoparticulate [17] as
can be seen from the in-vitro release studies of SLN-
NAC and drug permeation studies. The novel method
also ensures sizes small enough to avoid aggregation
over the shelf life of drug. Another very important
reason is the cost-effectiveness of the preparation
method. Mill method ensures preparation of SLN
within 2 h and the cost would be effectively only
the expenses incurred upon buying of reagents.
The shapes of the SLN-NAC were spherical and
obtuse which further elucidated that the SLN would
not cause irritation to the eye cornea as explained by
Khare et al [18]. Such nanoparticles also result in
better tolerance into the eye because of concentra-
tion of small amount of drug in nanoparticles than
eye drop. Moreover due to the general toxicity of free
drug, there is potential danger to other tissues sur-
rounding the lens which is not in case of nanoparti-
cles as pointed out by. Moreover the TEM
micrographs also point out that the there is no drug
leakage due to membrane breakage of the nanopar-
ticles despite the drug loading. The increased zeta
potential indicates that neither the SLN-NAC would
sediment nor will it aggregate to form larger particles.
Outright large negative value of the zeta potential
also indicates electrostatic repulsion between the
nanoparticles which will avoid nanoparticle aggrega-
tion. Encapsulation efficiency and drug loading effi-
ciency are found to be around 86% and 8%
respectively. These are extremely important indices
since with the in-vitro release profile of SLN-NAC;
these provide important information for therapeutic
purposes. Higher entrapment efficiency is as a result
of the very small sized nanoparticles (65–80 nm)
formed as a consequence of using bead mill method.
Additionally, due to the hydrophobicity and the small
size of the SLN-NAC, these penetrate the ocular bar-
rier easily and remain long in the circulation. The in-
vitro release studies agree with the solid lipid nano-
particles characteristic feature. The SLN are associated
with burst release of drugs [38] which is a disadvan-
tage turned into advantage in this case because of the
tear and blinking mechanism. The burst release is an
advantage in this case because of the major drug
release over a short period of is because of the drug
adsorption over the surface of nanoparticle and not in
the core which will be easily available for the treat-
ment of cataract.
The FTIR studies made an interesting observation.
It was seen that the peaks in the region of
1000–1339 cm−1 were not visible. These may be rea-
soned that the amount of NAC loaded in SLN-NAC is
lesser than pure drug. The more visible peaks claimed
successful drug loading in the SLN-NAC. The Bode
plot of the impediametric studies indicates an array
of impedance pattern which yields typical pattern of
least cell death (highest impedance values) in normal
HENC cell line which is very similar to the SLN-NAC
treated cells, followed by NAC treated cells. This typi-
cally indicates that the NAC is known to reduce the
oxidative stress [8] and the synergistic effects of nano-
particles and NAC causes a membrane stabilizing
effect and an antioxidant effect which tends to treat
as well as reverse cataract. Corneal hydration is an
integral part of study. The percentage of corneal
hydration indicates that there is normal deturges-
cence in the corneal stroma. This also specifies that
there is no loss or damage of the endothelial cells on
exposure to SLN-NAC and free NAC. There is no fluid
Figure 8. Corneal hydration % of SLN-NAC treated and Free
NAC treated Cornea.
Figure 9. Cytotoxicity of PBS (control), NAC and SLN-NAC.
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retained causing excessive corneal hydration which
may coincide with the clarity of lens. Briefly to say,
there is no corneal damage on contact with SLN-NAC
and free NAC.
We know that not only for ocular therapeutic drug
delivery, any application of nanoparticles for human
health has to be looked seriously into. The nanoparti-
culate system should not interfere with the living
tissues by causing toxicity or adverse reactions. This
is being exhibited by the cytotoxicity studies.
Although cytotoxicity studies indicate that there is
not a significant difference between the control NAC
and SLN-NAC. This may be attributed to the fact that
NAC has been previously regularly used as eye drops
for treatment of cataract in a lot of studies [6–8]. Our
work proves that SLN-NAC has even lower cell toxicity
than NAC. This study by us reinforces the physico-
chemical characterization of SLN and pronounces
them compatible for human ocular use. The key char-
acterization protocol like shape, size, entrapment effi-
ciency, drug loading, in-vitro studies and permeation
studies have specified that SLN-NAC may be more
useful than free NAC in eye drops for reversal and
treatment of cataract.
5. Conclusion
As evident from the study, we have invested much
effort in preparation and introduction of SLN in ocular
drug delivery. It was very logical to choose NAC
because of its established effects on cataractuous
lenses. Although the human corneal constructs need
to be worked upon, this seemed the only feasible way
of testing the efficacy of SLN-NAC. From a therapeutic
point of view, we have achieved the way to reduce
the number of injection to eye for treatment and
reversal of cataract by using SLN-NAC. The desired
effect was obtained with lowering of drug concentra-
tion in eye formulation and without causing any
damage to surrounding ocular tissues. This may
point out a significant extension of NAC for treatment
of cataract. Nevertheless, in spite of opening up a new
perspective, this studies mentioned above needs to
be replicated and thoroughly investigated for any
lacunae for further clinical implementation.
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